Hypertrophic cardiomyopathy mortality higher in women


  • Mary Corcoran
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A new study has found that hypertrophic cardiomyopathy (HCM) is associated with significant excess mortality through the life course, when compared with the general European population. 

The retrospective cohort study included 4,893 adults with HCM presenting at seven European referral centres in the United Kingdom, Spain, Greece and Italy between 1980 and 2013. Survival was compared using standardised mortality ratios (SMRs) calculated with data from Eurostat. 

The authors reported that during a median follow-up of 6.2 years, 721 patients reached the composite end point of all-cause mortality, aborted sudden cardiac death and heart transplant. 

Compared with the general population, adults with HCM had excess mortality throughout the age spectrum (SMR 2.0; 95% CI 1.48-2.63), with women having higher excess mortality than men. This excess mortality in women was identified throughout the age spectrum, whereas in men, mortality in those older than 60 years was similar to that of the general population. 

While the excess mortality was highest among patients presenting prior to the year 2000, it persisted in those presenting between 2006 and 2013, with the authors saying more needs to be done to reduce disease-associated complications.

The findings are published in JAMA Cardiology.